Objective: To examine the possible association of holotranscobalamin, the active fraction of serum cobalamin, with Alzheimer’s disease.
Methods: 51 patients with pathologically confirmed Alzheimer’s disease and 65 cognitively screened elderly controls were studied. Serum holotranscobalamin was measured by a new solid phase radioimmunoassay.
Results: Geometric mean levels showed no significant case–control differences for serum total cobalamin, but lower levels of holotranscobalamin in Alzheimer’s disease (41.1 pmol/l) than in controls (57.1 pmol/l) (p < 0.001). The odds ratio of Alzheimer’s disease was significant for low holotranscobalamin but not for low total cobalamin.
Conclusions: Disturbed cobalamin status is common in Alzheimer’s disease and accordingly measurement of holotranscobalamin should be considered in the assessment of cognitively impaired patients.
- vitamin B-12
- Alzheimer’s disease
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Competing interests: Both authors have had costs to participate in scientific meetings reimbursed by Axis-Shield Ltd.